Grant: Team Grant: E-Rare Joint Transnational Call
McGill University
$219,999.00
Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease
EF 2015-16
Résumé
Although the lifespan of people with cystic fibrosis has been extended considerably over the past few years, the improvements have largely come from better treatment of the symptoms and not the underlying cause of the disease. Effective drugs for treating CF based on actually targeting the defective protein, CFTR, in the lungs of patients are just now being developed. However, the most common form of CF still has no effective drug treatment. To address this, we will take small tissue samples from different patients with different forms of CF and turn them into stem cells that can be made to form lung or liver cells in the petri dish. These cells will then be used to screen for novel drugs that can improve the function of the defective CFTR protein and may be candidates for future therapies for patients.
Programme
Team Grant: E-Rare Joint Transnational Call
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
332061
Name
Hanrahan John W
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Research Foundation (Germany); Foundation for Science and Technology (Portugal); Cystic Fibrosis Canada; Fonds de recherche du Québec - Santé (FRQS); The Netherlands Organization for Health Research and Development (ZonMw); Ministero della Salute (Italy)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Induced pluripotent stem cells for identification of novel drug combinations targeting cystic fibrosis lung and liver disease
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$219,999
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Cystic Fibrosis; Drug Screens; Gene Correction; In Vitro Differentiation; Liver Cells; Lung Development; Stem Cells; Trafficking Mutations; Transgenic Reporters
Abstract
Although the lifespan of people with cystic fibrosis has been extended considerably over the past few years, the improvements have largely come from better treatment of the symptoms and not the underlying cause of the disease. Effective drugs for treating CF based on actually targeting the defective protein, CFTR, in the lungs of patients are just now being developed. However, the most common form of CF still has no effective drug treatment. To address this, we will take small tissue samples from different patients with different forms of CF and turn them into stem cells that can be made to form lung or liver cells in the petri dish. These cells will then be used to screen for novel drugs that can improve the function of the defective CFTR protein and may be candidates for future therapies for patients.
Competitiondate
201506
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hanrahan, John W
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #3~ $219,999~ $0~